T Cell-Tumor Interaction Directs the Development of Immunotherapies in Head and Neck Cancer

Figure 2

Comparison of the effects of a failed conventional therapy and the outcome of a hypothetical CSC-targeted immunotherapy. Currently applied conventional therapies target bulk tumor cells that are less resistant than CSC. This leads to initial shrinking of the tumor mass but eventually regrowth from residual CSC. An immunotherapeutic approach targeting CSC directly would cut off the rejuvenating supply of CSC and ultimately lead to tumor regression.